CompletedPhase 1NCT00383474
Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase
Studying Acute basophilic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Jeffrey Lancet, MDMoffitt Cancer Center
- Intervention
- Bortezomib(drug)
- Enrollment
- 35 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2006 – 2012
Study locations (1)
- Moffitt Cancer Center, Tampa, Florida, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00383474 on ClinicalTrials.govOther trials for Acute basophilic leukemia
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT01627041Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid LeukemiaNational Cancer Institute (NCI)
- ACTIVE NOT RECRUITINGNCT00898456Multidrug Resistance Genes in Patients With Acute Myeloid LeukemiaAlliance for Clinical Trials in Oncology